STAAR Surgical Company — Form 10-Q Summary
Reporting period: Three months ended March 29, 2024, compared with the three months ended March 31, 2023. The request metadata identifies “2023 Q1,” but the filing is the 2024 first-quarter Form 10-Q.
Business Context
STAAR designs, manufactures and sells implantable ophthalmic lenses and delivery systems, primarily implantable Collamer lenses (ICLs). The company operates as one ophthalmic surgical product segment and sells in more than 75 countries. ICLs represented 99.7% of net sales in the current quarter. The company phased out cataract IOL sales during 2023 and does not expect cataract IOL sales in 2024 or thereafter.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $77.4 million | $73.5 million | 5.2% increase |
| Gross profit | $61.0 million | $57.6 million | 6.0% increase |
| Gross margin | 78.9% | 78.3% | 60 basis-point increase |
| Operating income (loss) | $(2.3) million | $2.8 million | Declined by $5.1 million |
| Operating margin | (2.9%) | 3.8% | Declined 670 basis points |
| Net income (loss) | $(3.3) million | $2.7 million | Turned to loss |
| Diluted EPS | $(0.07) | $0.05 | Declined |
| Cash flow from operations | $21.7 million | $(5.1) million | Improved by $26.8 million |
ICL sales increased 9.2% to $77.2 million, including a 2% increase in units. Regional ICL sales increased 9% in APAC, 11% in EMEA and 12% in the Americas. Foreign currency movements reduced sales by approximately $1.0 million and contributed to a $2.3 million foreign-currency loss in other income.
General and administrative expense increased 28.3% to $23.2 million, primarily from higher outside services, facility costs and salary-related expenses. Research and development expense increased 29.8% to $13.4 million. Selling and marketing expense increased 1.3% to $26.7 million. Total selling, general and administrative expenses rose to 81.8% of sales from 74.5%.
The company recorded a $1.1 million income tax provision despite a pretax loss, resulting in a reported effective tax rate of negative 51.0%. Management attributes the variance from the 21% U.S. statutory rate primarily to taxes generated in foreign jurisdictions.
Liquidity, Cash Flow and Capital Structure
- Cash and cash equivalents were $224.0 million at March 29, 2024, up from $183.0 million at December 29, 2023.
- Available-for-sale investments were $28.1 million, down from $49.4 million; total cash and investments were $252.1 million.
- Working capital was $303.0 million, compared with $300.2 million at year-end 2023.
- Operating cash flow benefited substantially from a $29.8 million reduction in accounts receivable, partly offset by inventory and other working-capital uses.
- Capital expenditures were $5.2 million, compared with $2.9 million in the prior-year quarter. Property, plant and equipment increased to $72.3 million, including $45.1 million of construction in process.
- The filing does not report conventional funded debt. Finance lease obligations totaled $0.2 million, and operating lease liabilities totaled $35.5 million.
- Management believes available liquidity will meet anticipated working-capital, capital-expenditure and contractual obligations for at least 12 months from issuance of the financial statements.
Material Changes Versus the Prior Period
- Revenue growth was driven by ICL demand, particularly in China, Japan, India, distributor markets in EMEA and the United States and Canada.
- Gross margin improved modestly because of ICL product and geographic mix.
- Profitability deteriorated despite sales growth because operating expenses increased materially, particularly general and administrative and research and development costs.
- The company moved from net income to net loss, while operating cash flow improved due primarily to collections of accounts receivable.
- Other income declined from $1.9 million to $0.1 million, primarily because of higher foreign-exchange losses.
- China distributors represented 49% of current-quarter sales and 54% of consolidated trade receivables at quarter-end, creating significant geographic and customer concentration.
Guidance, Outlook, Risks and Unusual Items
The filing describes a strategy of expanding ICL availability, entering attractive new markets, increasing awareness of the ICL procedure and supporting surgeon training. It does not provide a clear quantitative revenue, earnings or margin guidance figure.
- Results may be affected by foreign-exchange movements, macroeconomic conditions, regulatory approvals, product launches, supply-chain constraints and demand for elective ophthalmic procedures.
- China distributors remain a significant concentration of sales and receivables.
- The company has a vendor accounting for more than 12% of consolidated accounts payable.
- Operating lease commitments totaled $45.4 million of undiscounted future payments, with $35.5 million recorded as the lease liability.
- Legal proceedings may include contractual, employment and product-liability matters. Management does not believe known claims are likely to have a material adverse effect, but unexpected outcomes could cause significant financial harm.
- Stock-based compensation expense was $6.3 million for the quarter, with $72.0 million of unrecognized compensation cost expected to be recognized over approximately two years.
- Capitalized cloud-based software implementation costs increased to $4.9 million and were not yet placed into service at quarter-end.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter.
Facts Investors Should Verify
- Whether ICL unit growth and regional sales momentum continue, particularly in China and other APAC markets.
- Whether elevated general and administrative and research and development spending moderates or continues to pressure operating margins.
- The sustainability of operating cash flow, given that the quarter benefited substantially from accounts-receivable collections.
- China distributor concentration, receivables collection risk and foreign-exchange exposure.
- Progress, timing and expected cost of construction in process and capitalized cloud-based software projects.
- Any quantitative guidance or updated outlook issued after the filing, as this Form 10-Q does not provide a clear numerical forecast.